Olink

Olink®
Part of Thermo Fisher Scientific

Exploring the bidirectional relationships between alzheimer's disease and cerebral small vessel disease: Insights from mendelian randomization

Journal of Stroke and Cerebrovascular Diseases, 2025

Shang H., Liu T., Gong W., Zhao Y.

Disease areaApplication areaSample typeProducts
CVD
Neurology
Pathophysiology
Plasma
O

Olink Target 96

Abstract

Objective
This study aimed to elucidate the bidirectional causal relationships between Alzheimer’s disease (AD), cerebral small vessel disease (CSVD), and the effect of inflammatory cytokines on AD and CSVD using Mendelian randomization (MR).
Method
We employed publicly available summary-level data from genome-wide association studies for AD, CSVD, and 91 inflammatory cytokines. Genetic variants strongly associated with each risk factor were selected as instrumental variables. The inverse variance weighted (IVW) method was primarily used for causal inference, with sensitivity analyses including MR-Egger and weighted median estimators.
Results
MR analysis revealed that genetically predicted CSVD significantly increased the risk of AD (odds ratio [OR] = 1.035, 95% CI, 1.015–1.056, P = 0.001). Conversely, AD did not significantly influence CSVD risk (OR = 0.878, 95% CI, 0.701–1.100, P = 0.257). Among inflammatory cytokines, Axin1 (OR = 1.082, 95% CI, 1.009–1.159, P = 0.026) and bNGF (OR = 1.061, 95% CI, 1.001–1.125, P = 0.048) increased AD risk, while CD5 (OR = 0.937, 95% CI, 0.887–0.991, P = 0.022) and CXCL11 (OR = 0.951, 95% CI, 0.912–0.992, P = 0.019) decreased AD risk. FGF19 (OR = 0.560, 95% CI, 0.405–0.773, P < 0.001) and TNFSF14 (OR = 0.744, 95% CI, 0.580–0.954, P = 0.020) were protective against CSVD.ConclusionOur findings suggest that CSVD may increase AD risk, while specific inflammatory cytokines exhibit differential associations with these conditions. Targeting vascular health and inflammation may offer promising therapeutic avenues for managing neurodegenerative diseases.

Read publication ↗